Nanocrystalline cerium dioxide efficacy for prophylaxis of erosive and ulcerative lesions in the gastric mucosa of rats induced by stress.
In our previous works, the important therapeutic properties of nanocrystalline cerium dioxide such as strong antioxidant ability, prebiotical and antibiotic activity were shown. Such properties were obtained due to stabilization of nanoparticles with precise size 3-7nm. Such modification of nanocrystalline cerium dioxide has contributed to its remarkable efficacy and low toxicity. We have carried out the investigation of toxicity of the nanodrug and revealed that in the condition of the acute toxicity test, LD 50 was 2000mg/kg when it was administered per os. This indicator is approximately 1000 times greater than effective dose of the compound that proved the possibility of its usage for humans. Considering the strong antioxidant properties of this substance, we have performed the investigation of the influence of nanocrystalline cerium dioxide on the erosive-ulcerative lesions in gastric mucosa of rats induced by Selye's restraint stress. It was established that the studied compound significantly reduced the lesions area by 58.3% (p<0.05) induced by Selye's restraint stress. The attenuation of inflammation and decrease of lipid peroxidation in the conditions of gastric lesions and prophylactic administration of nanocrystalline cerium dioxide were shown. That was confirmed by the decrease of pro-inflammatory cytokines content (interleukin (IL) 1β, 12B p40) and raise of anti-inflammatory cytokines content (IL-10 and transforming growth factor β). Measurement of lipid peroxidation products has proved the antioxidant properties of nanocrystalline cerium dioxide as it decreased the content of conjugated dienes and thiobarbituric acid active products in the conditions of gastric ulceration induced by stress.
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine.
Dmytro
D
Golyshkin
Department of Endocrinology, Bogomolets National Medical University, Kyiv, Ukraine.
Nazarii
N
Kobyliak
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine.
Oleksandr
O
Virchenko
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine.
Tetyana
T
Falalyeyeva
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine.
Tetyana
T
Beregova
Institute of Biology, Taras Shevchenko National University, Kyiv, Ukraine.
Lyudmyla
L
Ostapchenko
2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Martin
M
Caprnda
Department of Internal Medicine, F. D. Roosvelt Hospital, Banska Bytrica, Slovakia.
Lubomir
L
Skladany
Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia.
Radka
R
Opatrilova
Department of Gastroenterology, Faculty of Medicine, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
Luis
L
Rodrigo
Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia. Electronic address: kruzliakpeter@gmail.com.
Peter
P
Kruzliak
Zabolotny Institute of Microbiology and Virology, Kyiv, Ukraine.
Alexandr
A
Shcherbokov
Zabolotny Institute of Microbiology and Virology, Kyiv, Ukraine.
Mykola
M
Spivak
D000818:Animals; D002563:Cerium / Q000008:administration & dosage*; D003460:Crystallization; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage*; D056990:Post-Exposure Prophylaxis / Q000379:methods; D051381:Rats; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D013315:Stress, Psychological / Q000150:complications / Q000378:metabolism*; D016896:Treatment Outcome; D014961:X-Ray Diffraction
D002563:Cerium; C030583:ceric oxide
Cytokines; Erosive and ulcerative lesions; Gastric ulcer; Inflammation; Nanocrystalline cerium dioxide; Treatment